Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Avelumab (Bavencio) for metastatic Merkel Cell Carcinoma
(Final Recommendation Issued as of March 21, 2018)

Pembrolizumab (Keytruda) for Metastatic Urothelial Carcinoma
(Notification to Implement Issued as of March 19, 2018)

Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia 
(Notification to Implement Issued as of March 19, 2018)

Apalutamide (Brand Name: TBD) for Castrate Resistant Prostate Cancer
(Pending Submission as of March 16, 2018)

Obinutuzumab (Gazyva) for Follicular Lymphoma (previously untreated)
(Open for Input on Submission until March 29, 2018)

Pertuzumab-Trastuzumab (Perjeta-Herceptin) Combo Pack for Early Breast Cancer 
(Pending Submission as of March 9, 2018)

Cetuximab (Erbitux) for Left Sided Metastatic Colorectal Carcinoma 
(Pending Submission as of December 13, 2017)


Find a Drug Review